Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin;Sérová hladina retinol-binding proteinu 4 u obéznych s inzulínovou rezistenciou a jedincov s diabetom 2. typu liečených metformínom

Vnitrni Lekarstvi

Volumn 53, Issue 9, 2007, Pages 960-963

  Tajtáková, Mária ^a   Semanova Z ^a   Ivancova G ^b   Petrovicova J ^a   Donicova V ^b   Zemberova E ^c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b Interná a Diabetologická Ambulancia NZZ   (Slovakia)

^c RIA Laboratory   (Slovakia)

Author keywords

Metformin; Obesity; Retinol binding protein 4; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; RETINOL BINDING PROTEIN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; RETINOL-BINDING PROTEINS, PLASMA;

EID: 34948883950     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Anderwald C, Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev 2004; 1: 310-319.
2. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002; 3: 267-277.
3. Carvalho E, Kotani K, Peroni OD et al. Adipose - specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am J Physiol Endocrinol Metab 2005; 289: E551-E561.
4. Craig RL, Chu WS, Elbein SC. Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits. Mol Genet Metab 2006; PMID: 17174134.
5. Dorosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383.
6. Eldor R, Raz I. Lipotoxicity versus adipotoxicity - The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 2006; PMID: 16891032.
7. Gonzalez E, McGraw TE. Insulin signaling diverges into act dependent and independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol Biol Cell 2006; PMID: 16914513.
8. Graham TE, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.
9. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
10. Heilbronn L, Smith ER, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004; 28: S4: 12-21.
11. Cho YM, Youn BS, Lee H et al. Plasma retinol-binding protein 4 concentrations are eleved in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461.
12. Janke J, Engeli S, Boschmann M et al. Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 2805-2810.
13. Kanai M, Raz A, Goodman S. Retinol binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968; 47: 2025-2044.
14. Kotani K, Peroni OD, Minokoshi Y et al. GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin Invest 2004; 114: 1666-1675.
15. Kubota N, Terauchi Y, Kubota T et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and - independent pathways. J Biol Chem 2006; 281: 8748-8755.
16. Moon RJ, Bascombe LA, Holt RI. The addition of metformin in type I diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 2007; 9: 143-145.
17. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000; 348: 481-495.
18. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerence and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism 2007; 56: 24-29.
19. Polonsky KS. Retinol-binding protein 4, insulin resistance and type 2 diabetes. N Engl J Med 2006; 354: 2596-2598.
20. Radíková Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocrine Regulations 2003; 37: 188-194.
21. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an uptade. Clin Endocrinol (Oxf) 2006; 64: 355-365.
22. Steals B. Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin 2006; 22(Suppl 2): S27-S37.
23. Sharma PK, Bhansali A, Sialy R et al. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006; 65: 722-728.
24. Tajtáková M, Petrášova D, Petrovičova J et al. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocrine Regulations 2006; 40: 1-6.
25. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
26. Zorzano A, Palaci M, Gumá A. Mechanisms regulating GLUT4 glucose transporter expression and glucose transport in skeletal muscle. Acta Physiologica 2005; 183: 43-58.